Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
Status:
Completed
Trial end date:
1998-05-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor
I (IGF-I) on insulin secretion in children with hyperinsulinism.
II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this
patient population.
III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other
insulin dependent parameters, in this patient population.
Phase:
N/A
Details
Lead Sponsor:
FDA Office of Orphan Products Development
Collaborator:
Children's Hospital of Philadelphia
Treatments:
Complement Factor I Insulin Insulin, Globin Zinc Mecasermin Mitogens